COVID-19
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Following the success of its authorized vaccine against COVID-19, Moderna is boosting its efforts to develop preventative drugs in other viral areas.
The top COVID-19 story is on the pause of the Johnson & Johnson vaccine in the U.S. over rare blood clots. But it’s not the only news. Here’s a look.
The main concern remains the KN95 mask’s regulation and lack of standardization. Also, to know if you can reuse KN95 mask or not, follow this article.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
The U.S. CDC and the U.S. FDA have identified six cases in the U.S. of a “rare and severe” type of blood clot, which seems to be linked to the COVID-19 vaccine by Johnson & Johnson.
Six months after a COVID-19 diagnosis, more than 33% of people exhibited some form of brain damage, according to a study appearing in Lancet Psychiatry.
Researchers are leveraging the messenger RNA (mRNA) technology used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines for possible treatments for a range of other diseases, including HIV and cancer.
AstraZeneca’s diabetes drug Farxiga (dapagliflozin) failed to reach endpoints in a Phase III study as a potential treatment for hospitalized COVID-19 patients serious risk of developing complications.
Regeneron Pharmaceuticals announced the results from its Phase III trial of recently infected asymptomatic COVID-19 patients for its REGEN-COV (casirivimab with imdevimab) antibody cocktail.
PRESS RELEASES